Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

109 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Leptin increases hepatic triglyceride export via a vagal mechanism in humans.
Metz M, Beghini M, Wolf P, Pfleger L, Hackl M, Bastian M, Freudenthaler A, Harreiter J, Zeyda M, Baumgartner-Parzer S, Marculescu R, Marella N, Hannich JT, Györi G, Berlakovich G, Roden M, Krebs M, Risti R, Lõokene A, Trauner M, Kautzky-Willer A, Krššák M, Stangl H, Fürnsinn C, Scherer T. Metz M, et al. Among authors: harreiter j. Cell Metab. 2022 Nov 1;34(11):1719-1731.e5. doi: 10.1016/j.cmet.2022.09.020. Epub 2022 Oct 10. Cell Metab. 2022. PMID: 36220067 Free article. Clinical Trial.
Inhibition of 11β-HSD1 with RO5093151 for non-alcoholic fatty liver disease: a multicentre, randomised, double-blind, placebo-controlled trial.
Stefan N, Ramsauer M, Jordan P, Nowotny B, Kantartzis K, Machann J, Hwang JH, Nowotny P, Kahl S, Harreiter J, Hornemann S, Sanyal AJ, Stewart PM, Pfeiffer AF, Kautzky-Willer A, Roden M, Häring HU, Fürst-Recktenwald S. Stefan N, et al. Among authors: harreiter j. Lancet Diabetes Endocrinol. 2014 May;2(5):406-16. doi: 10.1016/S2213-8587(13)70170-0. Epub 2014 Feb 17. Lancet Diabetes Endocrinol. 2014. PMID: 24795254 Clinical Trial.
Suppression of plasma free fatty acids reduces myocardial lipid content and systolic function in type 2 diabetes.
Wolf P, Winhofer Y, Krssak M, Smajis S, Harreiter J, Kosi-Trebotic L, Fürnsinn C, Anderwald CH, Baumgartner-Parzer S, Trattnig S, Luger A, Krebs M. Wolf P, et al. Among authors: harreiter j. Nutr Metab Cardiovasc Dis. 2016 May;26(5):387-92. doi: 10.1016/j.numecd.2016.03.012. Epub 2016 Mar 31. Nutr Metab Cardiovasc Dis. 2016. PMID: 27118107 Clinical Trial.
Cardiometabolic Risk in Hyperlipidemic Men and Women.
Leutner M, Göbl C, Wielandner A, Howorka E, Prünner M, Bozkurt L, Harreiter J, Prosch H, Schlager O, Charwat-Resl S, Kautzky-Willer A. Leutner M, et al. Among authors: harreiter j. Int J Endocrinol. 2016;2016:2647865. doi: 10.1155/2016/2647865. Epub 2016 Nov 8. Int J Endocrinol. 2016. PMID: 27895666 Free PMC article.
Switch to Combined GLP1 Receptor Agonist Lixisenatide with Basal Insulin Glargine in Poorly Controlled T2DM Patients with Premixed Insulin Therapy: A Clinical Observation and Pilot Study in Nine Patients.
Harreiter J, Kosi-Trebotic L, Lukas A, Wolf P, Winhofer Y, Luger A, Kautzky-Willer A, Krebs MR. Harreiter J, et al. Diabetes Ther. 2017 Jun;8(3):683-692. doi: 10.1007/s13300-017-0249-4. Epub 2017 Mar 29. Diabetes Ther. 2017. PMID: 28357772 Free PMC article.
109 results